Swisscom profit drops 23% as Vodafone Italia costs weigh on results
AstraZeneca PLC (LSE:AZN, STO:AZN, NASDAQ:AZN) announced Monday that its issued share capital with voting rights stood at 1,550,712,906 ordinary shares of $0.25 each as of October 31. The company reported that no shares are held in treasury, resulting in a total number of voting rights of 1,550,712,906.
The disclosure was made in accordance with the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1. AstraZeneca stated that shareholders may use this figure as the denominator for calculating whether they are required to notify their interest in, or any changes to their interest in, the company under the relevant UK rules.
This information is based on a press release statement filed with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.